Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR
The Journal of ImmunologyPublished 1 November 2005Open access
Cyrille J. Cohen, Zhili Zheng, Regina B. Bray, Yangbing Zhao, Linda A. Sherman, Steven A. Rosenberg
Citations123
SJR quartileQ1
SJR score1.43
SNIP0.82
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is suggested that lymphocytes genetically engineered to express anti-p53 TCR may be of value for the adoptive immunotherapy of patients with a variety of common malignancies.
Abstract
The p53 protein is markedly up-regulated in a high proportion of human malignancies. Using an HLA-A2 transgenic mouse model, it was possible to isolate high-avidity murine CTLs that recognize class I-restricted human p53 epitopes. We isolated the alpha- and beta-chain of a TCR from a highly avid murine CTL clone that recognized the human p53(264-272) epitope. These genes were cloned into a retroviral vector that mediated high efficiency gene transfer into primary human lymphocytes. Efficiencies of >90% for gene transfer into lymphocytes were obtained without selection for transduced cells. The p53 TCR-transduced lymphocytes were able to specifically recognize with high-avidity, peptide-pulsed APCs as well as HLA-A2.1+ cells transfected with either wild-type or mutant p53 protein. p53 TCR-transduced cells demonstrated recognition and killing of a broad spectrum of human tumor cell lines as well as recognition of fresh human tumor cells. Interestingly, both CD8+ and CD4+ subsets were capable of recognizing and killing target cells, stressing the potential application of such a CD8-independent TCR molecule that can mediate both helper and cytotoxic responses. These results suggest that lymphocytes genetically engineered to express anti-p53 TCR may be of value for the adoptive immunotherapy of patients with a variety of common malignancies.
Keywords
Immunology and MicrobiologyMedicineBiochemistry, Genetics and Molecular Biology
NatureThe p53 tumour suppressor gene
3,828 Citations1991Arnold J. Levine, Jamil Momand +1 more
The cell cycle is composed of a series of steps which can be negatively or postively regulated by various factors, chief among the negative regulators is the p53 protein, which can lead to cancer.
ScienceCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2,812 Citations2002Mark E. Dudley, John R. Wunderlich +17 more
The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
New England Journal of MedicineA Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
1,828 Citations2003Salima Hacein‐Bey‐Abina, Christof von Kalle +9 more
The sustained correction of X-linked severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc gene into CD34+ cells in four of five patients with the disease has been reported.
Journal of Clinical OncologyAdoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
1,628 Citations2005Mark E. Dudley, John R. Wunderlich +19 more
Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.
The Journal of Experimental MedicineThe Central Role of CD4+ T Cells in the Antitumor Immune Response
1,342 Citations1998Kenneth E. Hung, Robert J. Hayashi +4 more
Analysis of the effector phase of tumor rejection induced by vaccination with irradiated tumor cells transduced to secrete granulocyte/macrophage colony-stimulating factor indicates a far broader role for CD4+ T cells in orchestrating the host response to tumor.
CellMutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome
1,336 Citations2004Kenneth P. Olive, David A. Tuveson +6 more
It is demonstrated that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.
CellGain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome
1,075 Citations2004Gene A. Lang, Tomoo Iwakuma +10 more
In vivo validation for the gain-of-function properties of certain p53 missense mutations are provided and a mechanistic basis for these phenotypes is suggested.
PubMedVersatile retroviral vectors for potential use in gene therapy.
678 Citations1994Robert G. Hawley, F H Lieu +2 more
A set of retroviral vectors whose capacity for high efficiency transduction of functional genes into undifferentiated murine embryonic and haematopoietic cells makes them ideally suited for preclinical studies with murine models and might prove useful in human gene therapy protocols.
Current Opinion in ImmunologyThe role of CD4+ T cell responses in antitumor immunity
669 Citations1998Drew M. Pardoll, Suzanne L. Topalian
Tumor antigens recognized by CD4+ T cells that are restricted by MHC class II are beginning to be defined in both murine and human tumors, which will provide the basis for new generations of antigen-specific tumor vaccines.
Nature reviews. CancerAdoptive-cell-transfer therapy for the treatment of patients with cancer
658 Citations2003Mark E. Dudley, Steven A. Rosenberg
These studies provide a blueprint for the wider application of adoptive-cell-transfer therapy, and emphasize the requirement for in vivo persistence of the cells for therapeutic efficacy.
Nature MedicineT–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients
575 Citations1996Stanley R. Riddell, Mark Elliott +9 more
An immunotherapy trial in which individuals seropositive for human immunodeficiency virus receive CD8+ HIV–specific cytotoxic T cells modified by retroviral transduction to express a gene permitting positive and negative selection suggests that strategies to render gene–modified cells less susceptible to host immune surveillance will be required for successful gene therapy of immunocompetent hosts.
ImmunogeneticsGenes regulating HLA class I antigen expression in T-B lymphoblast hybrids
570 Citations1985Russell D. Salter, David N. Howell +1 more
It is inferred that two complementary trans-acting factors mediate enhanced expression of HLA class I antigens in the hybrid, provided by a gene located on chromosome 6, derived from CEMR.3.
Nature MedicineColocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
560 Citations1996Helmut Hanenberg, Xiang Xiao +4 more
It is demonstrated that enhanced gene transfer into mammalian target cells is due to direct binding of retroviral particles to sequences within the fibronectin molecule.
The Journal of ImmunologyCharacterization of CD4+ CTLs Ex Vivo
540 Citations2002Victor Appay, John Zaunders +11 more
The Journal of Experimental MedicineCD4 T Cells and Their Role in Antitumor Immune Responses
521 Citations1999René E. M. Toes, Ferry Ossendorp +2 more
Charting the Th response against human melanoma as well as other tumors is important for the development of optimal anticancer vaccines and for the design of other T cell–related therapeutic modalities in cancer.
The Journal of ImmunologyTumor-specific cytolysis by lymphocytes infiltrating human melanomas.
520 Citations1989Suzanne L. Topalian, D. Solomon +1 more
These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.
ImmunityPrimary Antitumor Immune Response Mediated by CD4+ T Cells
472 Citations2005Alexandre Corthay, Dag K. Skovseth +6 more
A mechanism for immunosurveillance of MHC-II-negative cancer cells by tumor-specific CD4+ T cells by collaboration with macrophages through collaboration with T cell-derived IFNgamma is indicated.
Trends in Pharmacological Sciencesp53: 25 years after its discovery
425 Citations2004Lorne J. Hofseth, S. Perwez Hussain +1 more
The first 25 years of research on p53 are reviewed, which shows how this molecule continues to be studied intensively in biomedical research, including the fields of toxicology and pharmacology.
Nature MedicineEx vivo identification, isolation and analysis of tumor-cytolytic T cells
400 Citations2003Valerie Rubio, Tor B. Stuge +5 more
It is shown that tumor-cytolytic T cells are indeed elicited in patients after cancer vaccination, and that tumor reactivity is strongly correlated with efficient T-cell recognition of peptide-bearing targets.
Molecular and Cellular Biologyp53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.
372 Citations1985Arie Rogel, Malka Popliker +2 more
Proceedings of the National Academy of SciencesTargeting p53 as a general tumor antigen.
304 Citations1995Matthias Theobald, J Biggs +3 more
An experimental strategy is devised that exploits species differences in protein sequences to circumvent tolerance of high-affinity T cells and confirms the existence of broadly distributed determinants that may serve as targets for immunotherapy.
PubMedDevelopment of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
303 Citations1992Stefan Winter, John D. Minna +4 more
It is found that the ability of lung cancer patients to develop anti-p53 antibodies is correlated with the type of p53 mutation, but many patients have tumors with missense p53 mutations and did not develop anti, p53 antibodies.
Nature ImmunologyImmunotherapy through TCR gene transfer
277 Citations2001Helmut W. Kessels, Monika C. Wolkers +3 more
The genetic introduction of a virus-specific TCR into peripheral T cells in a mouse model system showed that T cells redirected by TCR gene transfer expanded upon viral infection of mice and efficiently homed to effector sites, suggesting that the redirection of T cells by T CR gene transfer is a viable strategy for the rapid induction of virus- or tumor-specific immunity.
Nature reviews. ImmunologyT-cell-receptor gene therapy
264 Citations2002Ton N. Schumacher
The pros and cons of TCR gene transfer as a strategy to induce defined virus- and tumour-specific T-cell immunity are discussed.
European Journal of ImmunologyIn vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53
263 Citations1993J. G. A. Houbiers, Hans W. Nijman +8 more
This work identified peptides of (mutant) p53 capable of binding to HLA‐A2.1 in an in vitro assay and obtained CD8+ cytotoxic T lymphocyte clones capable of specifically lysing target cells loaded with wild‐type or tumor‐specific mutant p53 peptides.
The Journal of Experimental MedicineTolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
256 Citations1997Matthias Theobald, J Biggs +4 more
PubMedInsulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
232 Citations1996Katia Scotlandi, Stefania Benini +7 more
Inactivation of the IGF-IR signaling pathway may be considered as an effective therapeutic modality for patients with Ewing's sarcoma andperipheral neuroectodermal tumor.
Human Gene TherapyTransfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions
230 Citations2005Marybeth S. Hughes, Yik Y. L. Yu +9 more
The genes for the alpha and beta chains of a highly reactive anti-MART-1 T-cell receptor were isolated from T-lymphocytes that mediated in vivo regression of tumor in a patient with metastatic melanoma and inserted into MSCV-based retroviral vectors.
The Journal of ImmunologyHigh Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
227 Citations2003Richard A. Morgan, Mark E. Dudley +8 more
The results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma.
Nucleic Acids ResearchRetroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy
207 Citations1992Richard A. Morgan, Larry A. Couture +4 more
The Journal of ImmunologyPrimary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines
196 Citations2005Yangbing Zhao, Zhili Zheng +4 more
The results strongly support the idea that redirection of normal T cell specificity by TCR gene transfer can have potential applications in tumor adoptive immunotherapy.
Advances in immunologyStrategies for immunotherapy of cancer
164 Citations2000Cornelis J.M. Melief, René E. M. Toes +4 more
The Journal of ImmunologyCutting Edge: MHC Class II-Restricted Killing In Vivo during Viral Infection
152 Citations2005Evan R. Jellison, Sung-Kwon Kim +1 more
This study demonstrates CD4-dependent MHC class II-restricted killing in lymphocytic choriomeningitis virus-infected mice in vivo using an in vivo cytotoxicity assay that features class III-expressing B cells as targets.
Proceedings of the National Academy of SciencesSpontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
152 Citations1996Mads A. Røpke, Jesper Hald +9 more
A cytotoxic T lymphocyte clone generated in vitro from the peripheral blood of a healthy HLA-A2-positive individual against a synthetic p53 protein-derived wild-type peptide was shown to kill squamous carcinoma cell lines derived from two head and neck carcinomas in a L9V/HLA-A 2 specific and restricted fashion.
BloodInduction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells
144 Citations2001Michael Rosenzweig, Michelle Connole +5 more
The data document the potential for foreign proteins expressed in CD34(+) hematopoietic cells and their progeny to induce antibody and CTL responses in the setting of a clinically applicable transplantation protocol.
ImmunityCooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR
141 Citations2005Jürgen Kuball, Frank Schmitz +9 more
The intentional redirection of both CD4+ Th cells and CD8+ CTL by the same high-affinity, CD8-independent, tumor-specific TCR could provide the basis for novel broad-spectrum cancer immunotherapeutics.
Clinical & Experimental ImmunologyThe physiological role of cytotoxic CD4+ T-cells: the holy grail?
126 Citations2004Victor Appay
The Journal of ImmunologyIdentification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism
125 Citations1996N S Williams, Víctor H. Engelhard
The existence of a population of CD4+ CTL that utilizes perforin re-emphasizes the likely importance of these cells in a classical defensive role against foreign pathogens, in addition to their already implied role as modulators of the immune response.
Molecular and Cellular Biologyp53 Cellular Tumor Antigen: Analysis of mRNA Levels in Normal Adult Tissues, Embryos, and Tumors
121 Citations1985Arie Rogel, Malka Popliker +2 more
In developing fetuses, a marked reduction of p53 mRNA levels was manifest from day 11 onwards, whereas the levels during organogenesis were comparable to those found in undifferentiated embryonic stem cells and in some tumors.
BloodRetrovirus-mediated gene transfer in primary T lymphocytes impairs their anti–Epstein-Barr virus potential through both culture-dependent and selection process–dependent mechanisms
120 Citations2002Delphine Sauce, Marie Bodinier +11 more
Overall, ex vivo gene modification of primary T cells can result in a significant reduction in EBV-reactive T cells through both culture-dependent and selection-dependent mechanisms.
The Journal of Experimental MedicineThe Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope
118 Citations1998Matthias Theobald, Thomas Ruppert +11 more
The results demonstrate that mutation of p53 not only leads to malignant transformation but may also, in some instances, affect immune surveillance and should be considered in the design of cancer vaccines.
The Journal of ImmunologyAccumulation of the p53 Protein Allows Recognition by Human CTL of a Wild-Type p53 Epitope Presented by Breast Carcinomas and Melanomas
116 Citations1998Sacha Gnjatic, Zhenzi Cai +4 more
It is shown that it is possible to obtain in vitro CTL lines that specifically recognize a p53 epitope spontaneously presented by a variety of HLA-A2+ transformed cell lines provided they display abnormal patterns of p53 expression and raises hopes for future immunotherapeutic approaches.
PubMedOverexpression of p53 is a late event in the development of malignant melanoma.
115 Citations1993Norman J. Lassam, Lynn From +1 more
The data suggest that overexpression of the p53 gene product is a late event in the progression of melanoma and consequently indicate that expression of this protein cannot be used as a marker to identify patients at high risk for the subsequent development of melanomas.
Cancer Immunology ImmunotherapyVaccination with p53-peptide?pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
111 Citations2004Inge Marie Svane, Anders Elm Pedersen +7 more
In conclusion, the strategy for p53-DC vaccination seems safe and without toxicity, and indications of both immunologic and clinical effect were found in heavily pretreated patients with advanced breast cancer.
Cancer ResearchSimultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor
104 Citations2005J. Roszkowski, Gretchen E. Lyons +4 more
The ability to confer class I MHC-restricted tumor cell recognition to CD4(+) T cells makes the TIL 1383I TCR an attractive candidate for T-cell receptor gene transfer-based immunotherapy.
PubMedFrequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
103 Citations2002Thomas K. Hoffmann, Albert D. Donnenberg +7 more
Frequency of epitope-specific T cells in the circulation of patients with squamous cell carcinoma of the head and neck did not correlate with p53 accumulation in the tumor, suggesting that other factors may contribute to the observed anti-p53 responses.
Cancer Immunology ImmunotherapyImmune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites
100 Citations2005Andreas E. Albers, Robert L. Ferris +4 more
Anti-wt p53 epitope-specific T cells and Treg preferentially localize to tumor sites in patients with HNC, but the effector cell population in TIL or PBMC was unresponsive to activation in the tumor microenvironment enriched in Treg.
European Journal of ImmunologyPrimary proliferative T cell response to wild‐type p53 protein in patients with breast cancer
99 Citations1995A F Tilkin, Richard Lubin +11 more
A T cell immune response in three patients with breast tumors who had mutated p53 gene and accumulated p53 protein is described, which is relevant to the immune processes leading to autoimmunity and has a bearing on anti‐p53 vaccine development in tumor immunology.
PubMedGeneration of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
98 Citations1999Kazuaki Chikamatsu, Koji Nakano +5 more
The results indicate that CTLs recognizing wild-type sequence epitopes can be generated from precursors present in PBLs obtained from some normal individuals using autologous dendritic cells as antigen-presenting cells and suggest that vaccine strategies targeting these epitope can lead to antitumor CTL generation, thereby emphasizing the therapeutic potential of p53-based cancer vaccines.
ScienceSelecting T Cell Receptors with High Affinity for Self-MHC by Decreasing the Contribution of CD8
96 Citations1992Linda A. Sherman, Sabine Hesse +3 more
By decreasing the affinity of the interaction with CD8, T cells whose receptors have relatively high affinities for self-MHC may survive negative selection.
Journal of Biological ChemistryLysine 271 in the transmembrane domain of the T-cell antigen receptor beta chain is necessary for its assembly with the CD3 complex but not for alpha/beta dimerization.
94 Citations1990Andrés Alcover, Roy A. Mariuzza +2 more
PubMedInduction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
91 Citations2002Sjoerd H. van der Burg, Anand G. Menon +9 more
The feasibility of a p53-specific therapeutic vaccination was investigated in cancer patients and demonstrated the feasibility, even in patients with advanced cancer, to elicit immune responses against the ubiquitously expressed tumor-associated auto-antigen p53.
The Journal of ImmunologyGeneration of T Cells Specific for the Wild-Type Sequence p53264–272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants
91 Citations2000Thomas K. Hoffmann, Koji Nakano +6 more
Journal of Clinical InvestigationAdoptive therapy with CD8+ T cells: it may get by with a little help from its friends
88 Citations2002William Ho, Cassian Yee +1 more
A murine model of immunity against the intracellular bacterium Listeria monocytogenes is used to evaluate a potential obstacle to T cell therapy, and the utility of providing an inflammatory stimulus (CD40 activation) to rescue otherwise ineffective adoptively transferred CD8 + T cells is demonstrated.
PubMedMHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
88 Citations1999Michael I. Nishimura, Dody Avichezer +8 more
These CD4+ T cells may represent a relatively rare population of T cells that express a T-cell receptor capable of cross-reacting with an MHC class I/peptide complex with sufficient affinity to allow triggering in the absence of the CD4 coreceptor.
Immunology Lettersp53, a potential target for tumor-directed T cells
87 Citations1994Hans W. Nijman, Sjoerd H. van der Burg +4 more
The wild-type p53 peptides with the highest affinity to the HLA-A*0201 molecule are identified using two assays: the previously described MHC peptide-binding assay and the peptide competition assay.
Molecular TherapyGenetic Modification of T Lymphocytes for Adoptive Immunotherapy
86 Citations2004Claudia Rössig, Malcolm K. Brenner
This review shows how genetic modification of T cells is being used preclinically and in patients to overcome limitations, by incorporation of novel receptors, resistance mechanisms, and control genes.
Human Gene TherapyRetrovirus-Mediated Gene Transfer in Primary T Lymphocytes: Influence of the Transduction/Selection Process and of <i>ex Vivo</i> Expansion on the T Cell Receptor β Chain Hypervariable Region Repertoire
81 Citations2000Christophe Ferrand, Éric Robinet +5 more
Overall, the HS-tk-expressing T cells used in the phase I/II clinical trial exhibit limited TCR repertoire skewing that is not due to the transduction/selection procedure, however, future T cell gene transfer protocols for clinical trials should be designed to take into account or possibly prevent such T cell repertoire alterations.
The Journal of ImmunologyTCR-Like Human Antibodies Expressed on Human CTLs Mediate Antibody Affinity-Dependent Cytolytic Activity
78 Citations2002Patrick Chames, Ralph A. Willemsen +6 more
This strategy, based on engraftment of T cells with in vitro engineered Abs, is an attractive alternative to the laborious, and in many cases unsuccessful, generation of highly potent tumor-specific T lymphocytes.
PubMedTissue culture studies on pleural effusions from breast carcinoma patients.
68 Citations1974Relda Cailleau, Bruce Mackay +2 more
It is demonstrated that pleural effusions provide a fertile source of tumor cells from which tumor cell lines can be established in patients with breast carcinoma.
PubMedP53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
66 Citations2003Kazuaki Chikamatsu, Andreas E. Albers +5 more
The ability of anti-p53 CD4(+) T cells to enhance the generation and antitumor functions of CD8(+) effector cells is demonstrated, demonstrating the crucial role of T helper-defined epitopes in shaping the immune response to multiepitope cancer vaccines targeting p53.
PubMedHigh steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
59 Citations2000Michel Vierboom, Suzanne Zwaveling +5 more
The data suggest that p53 turnover is related to the MHC class I-restricted presentation of p53-derived epitopes at the tumor cell surface and indicate that CTL-mediated immunotherapy that targets p53 can be applied to a wider range of tumors than has thus far been anticipated.
Human Gene TherapyA Simple and Reliable Method for Screening Retroviral Producer Clones Without Selectable Markers
56 Citations1997Masafumi Onodera, Akihiro Yachie +4 more
The RNA dot blot technique is a rapid (2 days) and reliable method to screen retroviral producer cells, thereby facilitating the generation and characterization of simplified retroViral producer cell clones.
Annals of the New York Academy of Sciencesp53: A Potential Target Antigen for Immunotherapy of Cancer
55 Citations2000Rienk Offringa, Michel Vierboom +3 more
Although p53‐specific CTL can readily be isolated from p53−/− mice, tolerance for this self antigen may prevent induction of similarly effective CTL in p53+/+ subjects, so more and more evidence is obtained for the pivotal role of tumor‐specific Th cells in the induction and effector phases of the antitumor response against tumors that lack class II MHC expression.
Journal of Molecular RecognitionRecombinant antibodies with MHC‐restricted, peptide‐specific, T‐cell receptor‐like specificity: new tools to study antigen presentation and TCR–peptide–MHC interactions
50 Citations2003Cyril J. Cohen, Galit Denkberg +3 more
The ability to transform the unique fine specificity but low intrinsic affinity of TCRs into high‐affinity soluble antibody molecules endowed with a TCR‐like specificity toward human tumor or viral epitopes is demonstrated.
International Journal of CancerFrequent mutations of the p53 gene in cutaneous melanoma of the nodular type
42 Citations1998Lars A. Akslen, Sissel E. Monstad +3 more
The results indicate that point mutations in exons 7 and 8 are more frequent than previously reported in primary melanomas, and such changes may be important for the development of certain melanoma subgroups.
Journal of Surgical ResearchThe Use of Transgenic Mice to Generate High Affinity p53 Specific Cytolytic T Cells
29 Citations1997Zhiwei Yu, X Liu +3 more
The possibility of targeting tumors, which overexpress p53, is demonstrated, and the possibility transferring the high affinity, p53 specific T cell receptors from the murine CTL to human T cells is raised.
Tumor BiologyThe <i>TP53</i> Tumor Suppressor Gene and Melanoma Tumorigenesis: Is There a Relationship?
27 Citations2004Mahmoud R. Hussein
PubMedTargeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
24 Citations2000X Liu, E. Peralta +2 more
These results represent the first time that a p53-specific TCR capable of recognizing hu cancer cells was heterologously expressed in a naive recipient cell, converting that cell to one recognizing hU tumor cells with mutated p53.
Advances in oto-rhino-laryngologyp53 as an Immunotherapeutic Target in Head and Neck Cancer
17 Citations2004Thomas K. Hoffmann, H. Bier +3 more
In vivo, immunoselection of tumors which become resistant to anti-p53 immune responses has important implications for future p53-based vaccination strategies and calls for modified approaches, in which altered peptide variants of the wt sequence p53 264-272 epitope are used in a vaccine in order to overcome unresponsiveness of T lymphocytes to the native epitope.
PubMedp53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
16 Citations1994Barnhill Rl, Javier S. Castresana +5 more
It is concluded that there is little evidence for significant p53 alteration in the initiation and development of melanoma and the role of the p53 gene in human melanoma is questionable.
…